We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

New ELISA-Type Immunologic Test Studies Seroprevalence Against SARS-CoV-2

By LabMedica International staff writers
Posted on 10 Feb 2021
Print article
Image: New ELISA-Type Immunologic Test Studies Seroprevalence Against SARS-CoV-2 (Photo courtesy of Polytechnic University of Valencia)
Image: New ELISA-Type Immunologic Test Studies Seroprevalence Against SARS-CoV-2 (Photo courtesy of Polytechnic University of Valencia)
A team of researchers has developed an affordable ELISA-type test that makes it possible to detect IgG and IgM antibodies against the SARS-CoV-2 virus from human serum.

The new ELISA-type immunologic test called DIFELISARS to study the seroprevalence against SARS-CoV-2 has been developed by researchers from the Polytechnic University of Valencia (Valencia, Spain) and is currently in the prototype phase. ELISA-type tests have been applied for decades in various fields of biomedical diagnosis, and they stand out due to their high sensitivity and reliability. Furthermore, they make it possible to analyze a high number of samples simultaneously - up to 120 samples in 180 minutes - which validates its suitability for broad population samplings such as seroprevalence studies.

The DIFELISARS test stands out due to its low cost compared to other existing tests on the market, as well as for its high sensitivity and reliability - classic characteristics of ELISA tests. The test provides a colorimetric signal, proportionate to the concentration of said antibodies, and makes it possible to characterize the sample by comparing positive and negative tests.

The researchers will now validate the test by analyzing a total 200 samples and will also study the differences in the immune response generated - antibody levels - among men and women from the analyzed serum samples. In the study, the team has already started gathering, preparing and characterizing approximately 50 serum samples from patients, which will be used as positive and negative COVID-19 tests. The samples taken will be increased until reaching the 200 needed to conduct the seroprevalence studies.

“The availability of a test of these attributes has now acquired critical importance, as it would allow easy, reliable and cheap monitoring of the individual response of each person during the current vaccination campaign,” said Ángel Montoya, director of the Immunotechnology line of the Ci2B at the Polytechnic University of Valencia.

“Although some ELISAs are currently on sale to detect antibodies against SARS-CoV-2 in human blood products, their price remains high and their real availability is scarce, because large amounts of institutions and governments around the world are trying to acquire them simultaneously in order to conduct their COVID-19 monitoring programs,” added Montoya. “We have worked on this project to tackle this, to get this low-cost test based on existing commercial immunoreactive products ready, which would help facilitate viral seroprevalence studies, while differentiating between sexes, in our immediate surroundings.”

Related Links:
Polytechnic University of Valencia

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
SARS-CoV-2 RT-PCR Assay
Reliance SARS-CoV-2 RT-PCR Assay Kit

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: The QIAstat-Dx Respiratory Panel Plus has received U.S. FDA clearance (Photo courtesy of QIAGEN)

New Respiratory Syndromic Testing Panel Provides Fast and Accurate Results

Respiratory tract infections are a major reason for emergency department visits and hospitalizations. According to the CDC, the U.S. sees up to 41 million influenza cases annually, resulting in several... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more